Aspirin Better Than Ticlopidine For Stroke Recurrence Prevention In Blacks
This article was originally published in The Tan Sheet
Aspirin appears to be a "better treatment for aspirin-tolerant black patients with noncardioembolic ischemic stroke" than ticlopidine (Roche's Ticlid) for prevention of recurrent stroke, myocardial infarction and vascular death, according to a recent study
You may also be interested in...
NINDS STUDY COMPARING ASPIRIN WITH TICLOPIDINE IN STROKE PREVENTION in African Americans is expected to begin patient accrual in early November. The study, comparing aspirin with ticlopidine (Roche/Syntex' Ticlid) for recurrent stroke prevention, will be conducted under the direction of researchers at The Rush-Presbyterian-St. Luke's Medical Center in Chicago. The five-year, $10.8 mil. study is funded by a grant from the National Institute of Neurological Disorders & Stroke.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning